Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14501 - 14525 of 15470 in total
Investigational
AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in chronic organ transplant rejection.
Investigational
Matched Description: … AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to …
IMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin sheath protecting the nerves.
Investigational
Matched Description: … Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and
PRA023 is a humanized monoclonal antibody directed to vascular endothelial growth inhibitor, also known as tumour necrosis factor (TNF)-like ligand 1A (TL1A) and TNF superfamily member 15. It is being investigated for ulcerative colitis.
Investigational
Matched Description: … vascular endothelial growth inhibitor, also known as tumour necrosis factor (TNF)-like ligand 1A (TL1A) and
Cofirasersen is under investigation in clinical trial NCT04441788 (A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB)).
Investigational
Matched Description: … Cofirasersen is under investigation in clinical trial NCT04441788 (A Study to Assess the Safety, Tolerability, and
Experimental
CG400549 has been used in trials studying the treatment of Skin Infection.
Investigational
Experimental
Molidustat is under investigation in clinical trial NCT03350321 (A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects).
Investigational
PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.
Investigational
PS386113 is a small molecule drug candidate under investigation for the treatment of inflammatory disorders. It is being developed by Schering-Plough and Pharmacopeia. Little information has been released about PS386113.
Investigational
Matched Description: … It is being developed by Schering-Plough and Pharmacopeia. …
Mimopezil is an acetylcholinesterase (AChE) inhibitor that has demonstrated potential use in the treatment of Alzheimer's disease. Mimopezil is a pro-drug that is rapidly absorbed and converted into huperzine A.
Investigational
Matched Description: … Mimopezil is a pro-drug that is rapidly absorbed and converted into huperzine A. …
AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's cancer cells.
Investigational
Matched Description: … immune response characteristics, that is designed to stimulate the patient's immune system to target and
An N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine that has R configuration (the antidepressant drug fluoxetine is a racemate comprising equimolar amounts of (R)- and (S)-fluoxetine).
Experimental
Matched Description: … configuration (the antidepressant drug fluoxetine is a racemate comprising equimolar amounts of (R)- and
Methamidophos is under investigation in clinical trial NCT03223753 (Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia in First Remission).
Investigational
Matched Description: … trial NCT03223753 (Web-Based Physical Activity Intervention in Improving Long Term Health in Children and
Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone is under investigation in clinical trial NCT02688101 (Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors).
Investigational
Matched Description: … cyclohexyl-4-methyl-3-thiosemicarbazone is under investigation in clinical trial NCT02688101 (Dose-finding and
Atabecestat is under investigation in clinical trial NCT02211079 (A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates).
Investigational
Matched Description: … 54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and
MK-2748 is under investigation in clinical trial NCT01593735 (A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)).
Investigational
Matched Description: … is under investigation in clinical trial NCT01593735 (A Multiple Dose Study to Evaluate the Safety and
Displaying drugs 14501 - 14525 of 15470 in total